Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C27H36N2O4.ClH |
| Molecular Weight | 489.047 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC(=O)C1=CC(CCN(C)CCC[C@](C#N)(C(C)C)C2=CC=C(OC)C(OC)=C2)=CC=C1
InChI
InChIKey=JHOAIMAMBNLIMD-YCBFMBTMSA-N
InChI=1S/C27H36N2O4.ClH/c1-20(2)27(19-28,23-11-12-24(31-4)25(18-23)32-5)14-8-15-29(3)16-13-21-9-7-10-22(17-21)26(30)33-6;/h7,9-12,17-18,20H,8,13-16H2,1-6H3;1H/t27-;/m0./s1
Etripamil is a non-dihydropyridine, L-type calcium channel blocker. Currently, etripamil is in Phase 3 development for the treatment of paroxysmal supraventricular tachycardia. Milestone Pharmaceuticals is also developing etripamil to provide rapid heartbeat control for patients living with atrial fibrillation and acute symptom relief for patients with angina.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Etripamil: Self-management of supraventricular tachycardia is not far away? | 2019-03 |
|
| Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm. | 2018-07-31 |
|
| High-density mapping of the slow pathway in a patient with atrioventricular nodal reentry given intranasal Etripamil during the NODE-1 study. | 2017-10 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
9TA9AC3H8Z
Created by
admin on Wed Apr 02 18:44:58 GMT 2025 , Edited by admin on Wed Apr 02 18:44:58 GMT 2025
|
PRIMARY | |||
|
2560549-35-9
Created by
admin on Wed Apr 02 18:44:58 GMT 2025 , Edited by admin on Wed Apr 02 18:44:58 GMT 2025
|
PRIMARY | |||
|
169490895
Created by
admin on Wed Apr 02 18:44:58 GMT 2025 , Edited by admin on Wed Apr 02 18:44:58 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
